Johnson & Johnson Reports Promising Findings for Xarelto for Reducing the Risk of Clinically Significant Bleeding

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban).

Source link
#Johnson #amp #Johnson #Reports #Promising #Findings #Xarelto #Reducing #Risk #Clinically #Significant #Bleeding